REG - Oncimmune Hldngs PLC - PDMR Dealing

Oncimmune HoldingsAnnouncement

18/12/2020 07:00

RNS Number : 0850J
  
Oncimmune Holdings PLC
  
18 December 2020
  
 

Oncimmune Holdings plc
 
("Oncimmune" or the "Company")
 
PDMR Dealing
 
Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, has been notified that Adam Hill, PDMR and Chief Executive Officer, has purchased 5,764 ordinary shares of £0.01 each in the Company ("Ordinary Shares") for £1.7348 per share on 17 December 2020.
 
Following this transaction, Adam has a total interest in the Company of 3,537,539 Ordinary Shares, representing approximately 5.6 per cent of the Company's issued Ordinary Share capital.
 
This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.
 
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
 







Details of the person discharging managerial responsibilities / person closely associated
 




a)
 


Name
 


Dr Adam Mark Hill




2
 


Reason for the notification




a)
 


Position/status
 


Chief Executive Officer




b)
 


Initial notification /Amendment
 


Initial notification




3
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 




a)
 


Name
 


Oncimmune Holdings plc




b)
 


LEI


213800HCYIWT6YPI1I02 




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)
 


Description of the financial instrument, type of instrument


Ordinary Shares of £0.01 each
 














Identification code


ISIN: GB00BYQ94H38














b)
 


Nature of the transaction
 


Purchase of shares




c)
 


Price(s) and volume(s)




























Price


Volume
















£1.7348


5,764






























d)
 


Aggregated information


















- Aggregated volume


Same as above














- Price


















e)
 


Date of the transaction
 


17 December 2020




f)
 


Place of the transaction


London stock exchange, AIM



 
For further information:
 
Oncimmune Holdings plc
Ron Kirschner, General Counsel and Company Secretary
contact@oncimmune.com 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHKKOBNFBDDPBD